ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Summary on May 3, 2018

May 3, 2018 - By Heather Owens

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

Total analysts of 2 have positions in Ziopharm Oncology (NASDAQ:ZIOP) as follows: 1 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 50%. Since December 11, 2017 according to StockzIntelligence Inc Ziopharm Oncology has 3 analyst reports. On Monday, March 5 H.C. Wainwright maintained ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) with “Buy” rating. On Thursday, December 14 H.C. Wainwright maintained the shares of ZIOP in report with “Buy” rating. Listed here are ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) PTs and latest ratings.

05/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $9.5 Maintain
14/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.5 Maintain
11/12/2017 Broker: Raymond James Rating: Hold

Ticker’s shares touched $4.29 during the last trading session after 0.92% change.ZIOPHARM Oncology, Inc. has volume of 299,753 shares. Since May 3, 2017 ZIOP has declined 39.46% and is downtrending. ZIOP underperformed the S&P500 by 51.01%.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology.The firm is worth $604.80 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to IntrexonÂ’s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma .Currently it has negative earnings. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.